EuroBioForum 2012 | 18 April 2012 Presentation by Edvard Beem, Co-director The Netherlands Organisation of Health Research and Development

1. The Netherlands organisation for
health research and development
Edvard Beem, co-director

2. PM: some wild perceptions
• PM will divert from blockbuster drugs to
orphan drugs
• PM will involve decisions not to treat 90
of 100 patients to be treated, that
means the courage to say NO

3. PM: an expert perception
PM is a paradigm shift…
• …from the one-treatment-fits-all approach
• …to strategies based on individual biological
makeup
• …moving away from the average patient towards
individualised assessments
• …determining a person’s individual health care
needs
• …catching up with current needs regarding
healthy living and ageing in our societies

4. P4 Medicine
• It is personalised
• Understands how genetic variation drives individual
treatment
• It is predictive
• Enables an upfront development of a tailored health strategy
• It is preventive
• Shift form illness to wellness
• It is participatory
• Empowers patients, informed choices, own responsibility

5. Potential impact of PM:
• …will affect ZonMw
• …in it’s long term policy
• …in it’s funding strategies
• …in it’s funding instruments
• …in it’s partnerships

6. New R&I policy in NL
• Launch of nine topsectors
• Among which Life Sciences & Health (LSH)
• Co-ordinating existing & new resources
• Shifts from public and private into PPP
• From golden triangle to platinum pentagon
• Innovation contracts with public and private
partners, including charities and insurers

7. DEPLOY
of innovative healthcare
SOCIETY and MARKET pull
solutions
NL Life
Sciences &
DESIGN Health
of best practices sector
DISCOVERY
of new insights KNOWLEDGE push

8. Innovation Contract LSH
Triple ambition
• To improve of health and quality of life
during life career
• To provide a major boost to the economy
through market growth for LSH enterprises
• To maintain a sustainable, efficient and
affordable health care sytem

9. Critical conditions for succes of LSH
DISCOVERY DESIGN DEPLOY
Increase the number of Accelerate the development Accelerate and broaden
promising leads process and improve the effective application
chance of success
1 Responding Dutch market with a
portal into the world
2 Optimized legal and regulatory issues
3 Well educated, entrepreneurial people
4 Good accessibility to the targeted funds
5 Strong, accessible knowledge base
6 Shared public-private innovation infrastructure
7 The Netherlands as one self-organized Life Sciences & Health sector
*

10. Social and economic demands Services Products and technologies
Society Economy
> Patient information/
Health
Healthcare biobanks
> E-health
QUALITY OF PRODUCTIVITY > Clinical decision
LIFE support
A more productive > …
population within Medical (Bio)-
Longer, healthier
Targeted therapies
Self-management
and beyond technology pharmacology
Early diagnosis
lives healthcare
Prevention
> Medicines
LIFE > Diagnosis (e.g. Lab-on- > Vaccines
SCIENCES chip) Techno-
& / > "Biologicals"
> (Molecular) imaging logy > …
HEALTH techn.
> Minimally invasive techn. > System
SUSTAINABLE BUSINESS > … Regenerative medicine biology
HEALTHCARE ACTIVITY > ...
Cost conatinment Companies prospering
Prosperity
on the (inter)national
markets > Biomaterials for
implants
> Stem cell
therapies
> …

11. Innovation Contract LSH
• Structuring the sector LSH
• Technology oriented approach
• Disease oriented approach
• Societal challenges oriented approach

12. Innovation contract LSH
• Structuring the sector LSH
• Technology-oriented approach
• Where strengths, connections and priorities of
public and private partners come together in a
natural and logical way
• Where people really meet
• Where concrete actions are taken
• Disease-oriented approach
• Societal challenges oriented approach

13. IC-LSH: ten roadmaps
• Molecular diagnostics
• Imaging and image-guided therapies
• Homecare & self-management
• Regenerative medicine
• Pharmacotherapy
• One Health
• Specialized nutrition, health & disease
• Global health, emerging diseases in emerging markets
• HTA and quality of life
• Enabling technologies & infrastructure
Ten roadmaps = ten strategic r&i agenda’s

14. Roadmaps # diseases
• Six detailed examples as showcase for
innovation along the health care chain
• Breast cancer
• Infectious diseases
• Rheumatic disorders
• Dementia
• Diabetes
• Parkinson’s disease

15. Roadmaps # health care chain
PREVENT DIAGNOSE CURE CARE
PRIORITIES ALONG THE HEALTHCARE CHAIN
Keep Diagnose Individua- Reduce Replace Move Reduce Enable
people early, lize side or repair from care symptoms chronic
healthy as before treatment effects bodily to cure , slow patients
long as complica- for best functions (unmet down to stay at
possible tions results needs) disease home
arise
Molecular diagnostics
Imaging & image-guided therapies
Homecare & self-management
Regenerative medicine
ROADMAPS
Pharmacotherapy
One health
Specialized nutrition, health & disease
Health technology assessment & quality of life
Enabling technologies & infrastructure
Global health, emerging diseases in emerging markets

16. Roadmaps # other topsectors
• Roadmaps LSH connect to:
• High Tech Systems and Materials
• Agro-Food
• Creative Industry
• Agriculture

17. Topsectors # EU Grand Challenges
• 4 topsectors match with the EIP-AHA
• Regarding its pillars
• Prevention, screening & early diagnosis
• Care & cure
• Active ageing & independent living
• Regarding its constituents
• ERANET’s, JPI’s, Art 185
• ESFRI’s

18. The Dutch Topsector Policy
Although the word is hardly mentioned,
the Topsector LSH+
breathes
Personalised Medicine

19. Next: Implementation
• Find barriers and enablers
• Find proper resources
• Find proper instruments
• Find lean & mean governing and managing
structure
• FIND TRUST AMONG THE PENTAGON
PARTNERS